Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature
Ocrelizumab is a recombinant humanized monoclonal antibody approved for the treatment of multiple sclerosis (MS) directed against CD20, a membrane glycosylated protein expressed on B-lymphocytes, but not plasma cells or neutrophils. Ocrelizumab structure and mechanism of action are related to rituximab, which has been used for years in the treatment of rheumatoid arthritis. The precise mechanisms through which ocrelizumab exerts its therapeutic clinical effects are not fully elucidated but, likely, CD20 binding leads to antibody-dependent cellular cytolysis and complement-mediated lysis of CD20 expressing cells [1].
from Journal of the Neurological Sciences https://ift.tt/37OLumI
from Journal of the Neurological Sciences https://ift.tt/37OLumI
Comments
Post a Comment